Management of Older Patients with Head and Neck Cancer: A Comprehensive Review

The projected increase in life expectancy over the next few decades is expected to result in a rise in age-related diseases, including cancer. Head and neck cancer (HNC) is a worldwide health problem with high rates of morbidity and mortality. In this report, we have critically reviewed the literatu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Advances in therapy 2023-05, Vol.40 (5), p.1957-1974
Hauptverfasser: Matos, Leandro L., Sanabria, Alvaro, Robbins, K. Thomas, Halmos, Gyorgy B., Strojan, Primož, Ng, Wai Tong, Takes, Robert P., Angelos, Peter, Piazza, Cesare, de Bree, Remco, Ronen, Ohad, Guntinas-Lichius, Orlando, Eisbruch, Avraham, Zafereo, Mark, Mäkitie, Antti A., Shaha, Ashok R., Coca-Pelaz, Andres, Rinaldo, Alessandra, Saba, Nabil F., Cohen, Oded, Lopez, Fernando, Rodrigo, Juan P., Silver, Carl E., Strandberg, Timo E., Kowalski, Luiz Paulo, Ferlito, Alfio
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The projected increase in life expectancy over the next few decades is expected to result in a rise in age-related diseases, including cancer. Head and neck cancer (HNC) is a worldwide health problem with high rates of morbidity and mortality. In this report, we have critically reviewed the literature reporting the management of older patients with HNC. Older adults are more prone to complications and toxicities secondary to HNC treatment, especially those patients who are frail or have comorbidities. Thus, this population should be screened prior to treatment for such predispositions to maximize medical management of comorbidities. Chronologic age itself is not a reason for choosing less intensive treatment for older HNC patients. Whenever possible, also older patients should be treated according to the best standard of care, as nonstandard approaches may result in increased treatment failure rates and mortality. The treatment plan is best established by a multidisciplinary tumor board with shared decision-making with patients and family. Treatment modifications should be considered for those patients who have severe comorbidities, evidence of frailty (low performance status), or low performance status or those who refuse the recommendations of the tumor board.
ISSN:0741-238X
1865-8652
1865-8652
DOI:10.1007/s12325-023-02460-x